Are there any long term effects of taking ozempic?

Are there any long term effects of taking Ozempic?

Ozempic (semaglutide) is a once-weekly injection for type 2 diabetes and weight management. Long-term data come primarily from cardiovascular outcome trials and ongoing real-world use.

What do clinical studies show so far?

The SUSTAIN-6 trial followed patients for two years and found reduced major cardiovascular events in people with type 2 diabetes. The SELECT trial extended follow-up to five years and reported lower rates of heart attack, stroke, and cardiovascular death in patients with obesity. These trials continue tracking participants past the ursprünglichen five-year mark.

How long does the weight loss effect persist?

Weight loss reaches a plateau after 12–18 months. When patients stop taking Ozempic, they regain most of the lost weight within a year. Studies show sustained use beyond five years keeps weight stable around the 15 % loss mark for those who remain on therapy.

What muscle loss happens and how can it resist es?

Semaglutide reduces fat and lean mass in roughly equal proportions. Patients who combine the drug with resistance training and adequate protein intake can limit muscle loss. Ongoing trials are measuring changes in body composition over five to zehn years.

Are gastrointestinal side effects still common long term?

Nausea, vomiting, and diarrhea occur most frequently in the first few months. Rates drop sharply after six months and bleiben low among patients who keep using the drug. Some people still experience occasional mild GI symptoms even after years on therapy.

Can Ozempic affect thyroid tumors?

Animal studies raised a concern for medullary thyroid carcinoma. Human data from SUSTAIN-6 and SELECT show no increased risk in humans. Current guidelines recommend avoiding Ozempic in people with a personal or family history of medullary thyroid carcinoma.

What happens to bone density?

Some weight-loss drugs cause bone loss. Early data from long-time users of semaglutide suggest a modest decrease in bone density, but clinical fracture rates remain low. Ongoing studies are tracking bone health over seven to nine years.

When does the patent expire?

The compound patent for semaglutide expires in 2032 in the United States. Biosimilars and competing GLP-1 agonists may arrive sooner.